Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Public ClinicalTrials.gov record NCT00220766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14 mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.
Study identification
- NCT ID
- NCT00220766
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 100 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2002
- Primary completion
- Jul 31, 2002
- Completion
- Feb 29, 2004
- Last update posted
- Sep 24, 2009
2002 – 2004
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Departments of Medicine and Microbiology | Birmingham | Alabama | 35294 | — |
| National Jewish Medical and Researach Center | Denver | Colorado | 80206 | — |
| International Center for Interdisciplinary Studies of Immunology | Washington D.C. | District of Columbia | 20007 | — |
| Allergy Associates of the Palm Beaches | North Palm Beach | Florida | 33408 | — |
| University of South Florida College of Medicine | St. Petersburg | Florida | 33701 | — |
| The Clinical Trials Center, Children's Hospital | New Orleans | Louisiana | 70118 | — |
| Allergy, Asthma, and Immunology | Omaha | Nebraska | 68124 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Optimed Research, LLC | Columbus | Ohio | 43235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00220766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2009 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00220766 live on ClinicalTrials.gov.